Independent Investment Research, The IDEA!

The IDEA!

Independent Investment Research

The Idea-Driven Equities Analyses company (the IDEA!) is an employee-owned boutique providing independent investment research and financial consultancy services with a clear focus on the Benelux countries. The company was founded in the summer of 2007 by Henk Slotboom and Maarten Verbeek, both with more than 35 years of professional experience in the financial sector. The IDEA! differentiates itself by focusing on adding value through self-initiated in-depth, idea-driven investment research, as well as by bespoke research assignments for institutional investors, hedge funds and private equity. In addition, we provide market intelligence, strategic research and – together with our business partners – consultancy services to businesses. In case you are interested in receiving more information, a sample of our products or an introductory meeting, please send a message to info@theidea.nl.

Equity Bottom-Up

<ul><li>In this edition: • Aegon | EGM Clears Path to US Redomiciliation • Ahold Delhaize | still holding the top-2 positions in e-commerce in the Netherlands • AkzoNobel/Axalta | EU remedies signal path to Axalta clearance • dsm-firmenich | policy uncertainty increasingly viewed as an investment constraint • Dutch housing market | supply improves; new-build affordability more of a challenge • Dutch household consumption | momentum strengthens, led by durable goods • E-com & Logistics | InPost: AI-driven customer service offers a second wave of efficiency gains</li></ul>

In this edition: • Aegon | EGM Clears Path to US Redomiciliation • Ahold Delhaize | still holding the top-2 positions in e-commerce in the Netherlands • AkzoNobel/Axalta | EU remedies signal path to Axalta clearance • dsm-firmenich | policy uncertainty increasingly viewed as an investment constraint • Dutch housing market | supply improves; new-build affordability more of a challenge • Dutch household consumption | momentum strengthens, led by durable goods • E-com & Logistics | InPost: AI-driven customer service offers a second wave of efficiency gains

Thematic (Sector/Industry)

<ul>
<li>dsm-firmenich delivered a stronger-than-expected start to 2026, with 1Q26 organic revenue growth of 4%, materially ahead of consensus expectations of ~1.5%, supported primarily by volume expansion rather than pricing.</li>
<li>Reported group revenue reached EUR 2.28bn, slightly above market forecasts despite a 6% adverse FX impact and the divestment effect from the animal nutrition business sold to CVC.</li>
<li>Adj. EBITDA of EUR 434m modestly exceeded consensus, demonstrating resilience in margins amid ongoing macroeconomic volatility.</li>
</ul>


dsm-firmenich delivered a stronger-than-expected start to 2026, with 1Q26 organic revenue growth of 4%, materially ahead of consensus expectations of ~1.5%, supported primarily by volume expansion rather than pricing.
Reported group revenue reached EUR 2.28bn, slightly above market forecasts despite a 6% adverse FX impact and the divestment effect from the animal nutrition business sold to CVC.
Adj. EBITDA of EUR 434m modestly exceeded consensus, demonstrating resilience in margins amid ongoing macroeconomic volatility.


<ul>
<li>Three candidates remain for the purchase of dsm-firmenich's Animal Health &amp; Nutrition (AHN) division: private equity firms CVC and Apollo, and Dutch feed producer Nutreco.</li>
<li>This is reported by Dutch financial daily FD, citing anonymous sources. This deal, which has an estimated value of approx.</li>
<li>EUR 2.8bn, is among the largest Dutch transactions of the year, though the acquisition environment remains subdued.</li>
</ul>


Three candidates remain for the purchase of dsm-firmenich's Animal Health &amp; Nutrition (AHN) division: private equity firms CVC and Apollo, and Dutch feed producer Nutreco.
This is reported by Dutch financial daily FD, citing anonymous sources. This deal, which has an estimated value of approx.
EUR 2.8bn, is among the largest Dutch transactions of the year, though the acquisition environment remains subdued.


What's New(s) in Amsterdam - 7 July (dsm-firmenich | Philips | TomTom)

<ul>
<li>According to Bloomberg, several private equity parties are looking at a possible takeover of dsmfirmenich 's animal feed division.</li>
<li>CVC Capital Partners, Apollo, Bain Capital and Lone Star are among those interested.</li>
<li>dsm-firmenich announced last year that it would be divesting the division.</li>
</ul>


According to Bloomberg, several private equity parties are looking at a possible takeover of dsmfirmenich 's animal feed division.
CVC Capital Partners, Apollo, Bain Capital and Lone Star are among those interested.
dsm-firmenich announced last year that it would be divesting the division.


What's New(s) in Amsterdam - 7 April (dsm-firmenich | Shell | InPost | B&S Group | TomTom)

<ul>
<li>On February 13, 2025, when publishing in FY24 results, dsm-firmenich announced its intention to repurchase ordinary shares with an aggregate market value of EUR 1bn and reduce its issued capital.</li>
<li>This share repurchase program will start for an initial EUR 500m and will be increased to EUR 1bn upon the completion of the previously announced sale of the company’s stake in the Feed Enzymes Alliance.</li>
<li>As of today, April 1, 2025, the company intends to begin repurchasing ordinary shares for a total amount of EUR 580m, of which EUR 80m to cover commitments under the Group’s share-based compensation plans and EUR 500m to reduce its issued capital.</li>
</ul>


On February 13, 2025, when publishing in FY24 results, dsm-firmenich announced its intention to repurchase ordinary shares with an aggregate market value of EUR 1bn and reduce its issued capital.
This share repurchase program will start for an initial EUR 500m and will be increased to EUR 1bn upon the completion of the previously announced sale of the company’s stake in the Feed Enzymes Alliance.
As of today, April 1, 2025, the company intends to begin repurchasing ordinary shares for a total amount of EUR 580m, of which EUR 80m to cover commitments under the Group’s share-based compensation plans and EUR 500m to reduce its issued capital.


What's New(s) in Amsterdam - 1 April (dsm-firmenich | Shell)

Switzerland

DSM-Firmenich AG is an innovator in nutrition, health, and beauty products. The Company reinvents, manufactures, and combines vital nutrients, flavors, and fragrances. DSM-Firmenich serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DSM-Firmenich (DSFIR NA)

PostNL NV - What's News in Amsterdam

In this edition: • Aegon | EGM Clears Path to US Redomiciliation • Ahold Delhaize | still holding the top-2 positions in e-commerce in the...

The IDEA!

What's News in Amsterdam

Adj. EBITDA of EUR 434m modestly exceeded consensus, demonstrating resilience in margins amid ongoing macroeconomic volatility.

The IDEA!

What's New(s) in Amsterdam - 7 July (dsm-firmenich | Philips | TomTom)

Three candidates remain for the purchase of dsm-firmenich's Animal Health & Nutrition (AHN) division: private equity firms CVC and Apollo, and...

The IDEA!

What's New(s) in Amsterdam - 7 April (dsm-firmenich | Shell | InPost | B&S Group | TomTom)

According to Bloomberg, several private equity parties are looking at a possible takeover of dsmfirmenich 's animal feed division.

The IDEA!

What's New(s) in Amsterdam - 1 April (dsm-firmenich | Shell)

On February 13, 2025, when publishing in FY24 results, dsm-firmenich announced its intention to repurchase ordinary shares with an aggregate market...

The IDEA!

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)